Clinical Trial: NCT02442349
Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-01-09 |
Study Overview
Brief Summary
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene
Official Title
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene.
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: AZD9291
Other Study ID Numbers
- D5160C00017
Start Date (Actual)
2015-06-22
Primary Completion Date (Actual)
2016-03-04
Study Completion Date (Actual)
2025-11-28
Enrollment (Actual)
171
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-01-09 |
Study Overview
Brief Summary
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene
Official Title
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene.
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: AZD9291
Other Study ID Numbers
- D5160C00017
Start Date (Actual)
2015-06-22
Primary Completion Date (Actual)
2016-03-04
Study Completion Date (Actual)
2025-11-28
Enrollment (Actual)
171
Study Type
Interventional
Phase
Phase 2